NCT07054099View on ClinicalTrials.gov

A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

474

Participants

Timeline

Start Date

March 31, 2026

Primary Completion Date

August 31, 2027

Study Completion Date

July 31, 2036

Conditions
Varicella (Chickenpox)Chickenpox Vaccine
Interventions
BIOLOGICAL

MG1111 (Barycela inj.)

MG1111 (Barycela inj.)

BIOLOGICAL

VARIVAX™

Varivax™

Sponsors

Lead Sponsor

GC Biopharma Corp
All Listed Sponsors
lead

GC Biopharma Corp

INDUSTRY

NCT07054099 - A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years | Biotech Hunter | Biotech Hunter